For global biopharma companies looking to maximise value creation across geographies, China’s clinical trials market offers huge opportunities.
China is a rapidly developing market for clinical trials, having recorded the largest number of new trials between 2017 and 2021. Western biopharma companies can take advantage of regulatory reforms which make it easier to enter China’s market. Chinese companies can enter the developed markets of the US and Europe through strategic partnerships and engagement with regulatory bodies.
This paper presents a detailed analysis of clinical trial regulations in China and the US. It offers global biopharma companies a guide to their options for clinical development.
Based on extensive research, GlobalData and Asia Pacific CRO Novotech provide detailed insight to equip global biopharma companies to capitalise on some of the world’s most important markets for clinical trials.